Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H14F2N2O2 |
| Molecular Weight | 232.2272 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](N1C[C@@H](CC1=O)C=C(F)F)C(N)=O
InChI
InChIKey=ANWPENAPCIFDSZ-RQJHMYQMSA-N
InChI=1S/C10H14F2N2O2/c1-2-7(10(13)16)14-5-6(3-8(11)12)4-9(14)15/h3,6-7H,2,4-5H2,1H3,(H2,13,16)/t6-,7+/m1/s1
Seletracetam, a pyrrolidone derivative is a new drug in epilepsy development. Seletracetam has high binding affinity to the synaptic vesicle 2A (SV2A) protein. In addition, was discovered, that the drug bound to N-type calcium channels and inhibited high-voltage-activated Ca2+ currents and intracellular Ca2+ increase. Seletracetam participated in Phase III clinical trials; however, all these studies for the treatment of epilepsy were terminated. Moreover, it is unknown whether planned phase IIb/III trials will begin.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Drugs in development for Parkinson's disease: an update. | 2006 Jan |
|
| Diverse mechanisms of antiepileptic drugs in the development pipeline. | 2006 Jun |
|
| Modifications of antiepileptic drugs for improved tolerability and efficacy. | 2008 Feb 14 |
|
| Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy. | 2009 Jul 1 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C264
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
||
|
NCI_THESAURUS |
C1509
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
QQ-110
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104983
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
357336-74-4
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
SELETRACETAM
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
300000034404
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
9942725
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
RFR2CH3QZK
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
DTXSID30905079
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
8641
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
C66534
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
DB05885
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
